Nrf2‐mediated adenylosuccinate lyase promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma cells through ferroptosis escape
Journal of Cellular Physiology · 2024-12 · 239 (12)
DOI: 10.1002/jcp.31416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, online erschienen am 20.08.2024. Verfasst von Tung-Wei Hsu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, NF-E2-Related Factor 2, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Taipei Medical University, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Pancreatic cancer has one of the highest fatality rates and the poorest prognosis among all cancer types worldwide. Gemcitabine is a commonly used first‐line therapeutic drug for pancreatic cancer; however, the rapid development of resistance to gemcitabine treatment has been observed in numerous patients with pancreatic cancer, and this phenomenon limits the survival benefit of gemcitabine. Adenylosuccinate lyase (ADSL) is a crucial enzyme that serves dual functions in de novo purine biosynthesis, and it has been demonstrated to be associated with clinical aggressiveness, prognosis, and worse patient survival for various cancer types. In the present study, we observed significantly lower ADSL levels in gemcitabine‐resistant cells (PANC‐1/GemR) than in parental PANC‐1 cells, and the knockdown of ADSL significantly increased the gemcitabine resistance of parental PANC‐1 cells. We further demonstrated that ADSL repressed the expression of CARD‐recruited membrane‐associated protein 3 (Carma3), which led to increased gemcitabine resistance, and that nuclear factor erythroid 2‐related factor 2 (Nrf2) regulated ADSL expression in parental PANC‐1 cells. These results indicate that ADSL is a candidate therapeutic target for pancreatic cancer involving gemcitabine resistance and suggest that the Nrf2/ADSL/Carma3 pathway has therapeutic value for pancreatic cancer with acquired resistance to gemcitabine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Surgery, Division of General Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
- School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan.
- Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.
- Department of Surgery, Division of General Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Ching-Feng Chiu, Po-Hsiang Liao, Yen-Hao Su
Förderung
- Taipei Medical University
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Hsu, T. W., Wang, W. Y., Chen, A., Chiu, C. F., Liao, P. H., Chen, H. A., Su, C. M., Shen, S. C., Tsai, K. Y., Wang, T. H., & Su, Y. H. (2024). Nrf2‐mediated adenylosuccinate lyase promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma cells through ferroptosis escape. Journal of Cellular Physiology, 239(12). https://doi.org/10.1002/jcp.31416
Vancouver
Hsu TW, Wang WY, Chen A, Chiu CF, Liao PH, Chen HA, et al. Nrf2‐mediated adenylosuccinate lyase promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma cells through ferroptosis escape. Journal of Cellular Physiology. 2024;239(12). doi:10.1002/jcp.31416
BibTeX
@article{Hsu2024,
author = {Hsu, Tung-Wei and Wang, Wan-Yu and Chen, Alvin and Chiu, Ching-Feng and Liao, Po-Hsiang and Chen, Hsin-An and Su, Chih-Ming and Shen, Shih-Chiang and Tsai, Kuei-Yen and Wang, Tzu-Hsuan and Su, Yen-Hao},
title = {Nrf2‐mediated adenylosuccinate lyase promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma cells through ferroptosis escape},
journal = {Journal of Cellular Physiology},
year = {2024},
volume = {239},
number = {12},
doi = {10.1002/jcp.31416}
}
EUVIMED